Navigation Links
VIVUS to Present at the Deutsche Bank BioFEST Conference
Date:12/1/2011

s. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  p
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results
2. VIVUS to Present at the BioCentury NewsMakers Conference
3. VIVUS to Participate in Three Investor Conferences in September
4. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
5. VIVUS Reports First Quarter 2011 Financial Results
6. VIVUS to Present at Four Upcoming Investor Conferences in May
7. VIVUS to Present at the 10th Annual Needham Healthcare Conference
8. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
9. VIVUS to Present at Four Upcoming Investor Conferences
10. VIVUS to Present at Two Upcoming Investor Conferences
11. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... devices with unprecedented efficiency and data storage ... use built-in electric polarizations to read and ... most popular data-driven technology. But ferroelectrics must ... including a curious habit of "forgetting" stored ... U.S. Department of Energy,s Brookhaven National Laboratory ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
(Date:8/18/2014)... 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ("we" ... and marketing of innovative therapies for autoimmune diseases in ... a second notice of TNI BioTech,s annual meeting of ... Noreen Griffin , founder and CEO of TNI ... participation in the Annual Meeting. On behalf of our ...
Breaking Biology Technology:BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... March 20 PharmAthene, Inc.,(Amex: PIP ) ... chemical threats, today reported the company will delay ... 31, 2007. The earnings,release was previously scheduled for ... date and time of its earnings release and ...
... (NASDAQ: ANPI , TSX: ANP), a global ... participate in the Credit Suisse,Global Leveraged Finance Conference, ... Mr. Thomas Bailey, Angiotech,s Chief Financial Officer, ... at approximately 8:00 am Mountain,Time. A question and ...
... S.C., March 20 On January 7,2008, Signalife ... ("AMEX") pursuant to which it advised that Signalife ... equity threshold required for,continued listing under AMEX Rules ... Signalife,s market capitalization to less than,$50 million, which ...
Cached Biology Technology:AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2
(Date:8/20/2014)... discovered that acral melanomas the rare type of skin ... genetically distinct from other more common types of skin cancer, ... journal Pigment Cell & Melanoma Research . , Acral ... of the feet, nail-beds and other hairless parts of the ... caused by UV damage from the sun. , The team, ...
(Date:8/20/2014)... Biting into a chili pepper causes a burning spiciness ... Scientists exploring the chili pepper,s effect are using their ... kinds of pain, which can be caused by inflammation ... compound, which is being tested in clinical trials, in ... Tafesse and colleagues explain that decades ago, scientists had ...
(Date:8/20/2014)... poor experience higher cortisol levels in pregnancy and give ... hormone, putting them at greater risk for serious ... from the University of Colorado Denver. , The study, ... Human Biology , is the first to measure cortisol ... status of their mothers during pregnancy. , "There have ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2CU Denver researcher shows economic disparities impact infant health 2
... The old excuse, "I am only overweight because ... uncover ever more evidence that the way our bodies ... is different for every person. The budding discipline of ... manner. Nutrition scientists and food chemists at the Technische ...
... published today in Science , researchers from Cambridge, ... plasticity in how transcription factors, the proteins that bind ... their function over large evolutionary distances. The text ... that they regulate by binding to short, sequence-specific lengths ...
... Coral reef ecosystems are highly valued for ... multibillion dollar reef fishing and tourism industries, but ... growth and over-exploitation. The National Institute ... accepting applications for its Investigative Workshop, Modeling Reef ...
Cached Biology News:Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 2Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 3Rewiring of gene regulation across 300 million years of evolution 2
... routine agarose gel electrophoresis into an automated, ... This bufferless, pre-cast system is ideal for ... digests, and more. Fully automated, robot-compatible, and ... 96 system makes your high-throughput screening assignments ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
... PCR Cloning Kit, 40 reactions. Optimized ... of all PCR products with blunt ... approaches by offering consistently better signal-to-noise ... more positive clones.Amplicons generated by proof-reading ...
... Clone/PAD: ZMD.368. Immunogen: Synthetic ... of the human WNT2B/WNT13 protein. ... human mouse and rat WNT2B/WNT13 proteins. ... isoforms. Reactivity: Mouse Human Rat ...
Biology Products: